Published in Hepatitis Weekly, January 23rd, 2006
Sirna completed its preclinical evaluation of the efficacy of Sirna-AV34 and has begun cGMP manufacturing for its phase 1 clinical studies. Sirna expects to initiate IND-enabling toxicology studies in the first quarter of 2006 followed by the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).
Sirna-AV34 is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.